Skip to main content
Message Font: Serif | Sans-Serif
 
No. of Recommendations: 0
balance sheet commentary re: managing balance sheet/
accelerating receivables collections, of not much importance at all to we stockholders.
the trading range of the stock has been absurdly tight
ranging from a paltry 42 to 43 3/4..this stock has been comatose....
Pfizer needs a blockbuster drug announcement ASAP.
the multiple is high, the political climate is quite hostile, the bio-techs are in vogue and exciting,
generics litigations are going against big-drug companies...with all these negative factors in play, does speeding-up receivables sound like it's of much importance vs. blockbuster drugs ??? PLEASE !!!
Print the post Back To Top
No. of Recommendations: 8
balance sheet commentary re: managing balance sheet/
accelerating receivables collections, of not much importance at all to we stockholders.
the trading range of the stock has been absurdly tight
ranging from a paltry 42 to 43 3/4..this stock has been comatose....
Pfizer needs a blockbuster drug announcement ASAP.
the multiple is high, the political climate is quite hostile, the bio-techs are in vogue and exciting,
generics litigations are going against big-drug companies...with all these negative factors in play, does speeding-up receivables sound
like it's of much importance vs. blockbuster drugs ??? PLEASE !!!

<><><><<><><>


Sir,

You are posting on the rulemaker board. This is a LONG term strategy. If a company is to grow earnings over decades it needs to manage its cash flow well. It needs CASH to invest in R & D to find those blockbuster drugs...not just this year but next year and beyond. The political climate, the "trading range" (whatever the heck that meands) and the rage for other sectors are all short term considerations. If you are investing for a short term pop ALL your concerns are valid. If you are investing in for the long run I suggest that you pay attention to Mr. Weiss. He's taught me a great deal.

-Mark
Print the post Back To Top